The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2017 | Is the CR of MM patients a good objective for treatment?
Maria-Victoria Mateos, MD, PhD, from the University Hospital of Salamenca, Salamenca, Spain, discusses the rationale for analysing the complete response (CR) as the objective for treatment of elderly patients with multiple myeloma (MM). With conventional treatment, few patients achieve CR, as described by Dr. Mateos, but with the development of novel agents, there is potential for using CR as the main objective in the treatment of elderly MM patients. This interview was filmed at the American Society of Oncology (ASCO) 2017 Annual Meeting in Chicago, IL.
